("Faron or the "Company")
Decisions of the Board of Directors
Company announcement,
At the meeting of the Board held following the AGM,
In addition, the Board elected the Chairs and other members to the Board committees from among its members as follows:
Markku Jalkanen was elected the Chair of the Audit Committee and Marie-Louise Fjällskog andJohn Poulos were elected as members of the Audit Committee.Tuomo Pätsi was elected the Chair of the Nomination Committee andMarkku Jalkanen andChristine Roth were elected as the other members of the Nomination Committee.John Poulos was elected as the Chair of the Remuneration Committee andTuomo Pätsi andChristine Roth were elected as the other members of the Remuneration Committee.John Poulos was elected as the Chair of the Business Development Committee andMarkku Jalkanen andJuho Jalkanen were elected as the other members of the Business Development Committee
For more information please contact:
Investor Contact
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
ICR Consilium
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Phone: +44 (0) 207 213 0880
Phone: +44 (0) 20 7418 8900
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.
https://news.cision.com/faron-pharmaceuticals-oy/r/decisions-of-the-board-of-directors,c3957588
https://mb.cision.com/Main/19398/3957588/2715052.pdf
(c) 2024 Cision. All rights reserved., source